Divis Laboratories Ltd
About
Divi’s Laboratories is an Indian pharmaceutical company headquartered in Hyderabad. It provides active pharmaceutical ingredients (APIs), registered starting materials, and intermediates to more than 100 countries across the world. With the world’s largest API manufacturing facility to its name, Divi’s is among the top 3 API manufacturers in the world. In addition to APIs, the company provides custom manufacturing solutions to 12 out of the top 20 Big Pharma companies and nutraceuticals like astaxanthin, lycopene, beta carotene, and vitamins. The company already produces 30 APIs, along with 10 in the pipeline, commercially. Its facilities in both Hyderabad and Vizag have been approved by health agencies of countries like the US, the UK, Canada, Ireland, Germany, and more.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 8293 2.5% | 8089 -15.7% | 9598 35.0% | 7111 25.0% | 5690 5.2% | 5406 35.1% | 4002 -4.3% | 4180 8.6% | 3848 13.2% | 3399 24.7% | 2725 18.9% | 2292 18.8% | 1930 46.3% | 1319 23.4% | 1069 -19.1% | 1321 - |
| Net Operating Income (INR Cr) | 7845 1.00% | 7767 -13.31% | 8960 28.56% | 6969 29.20% | 5394 9.06% | 4946 27.10% | 3891 -4.25% | 4064 7.63% | 3776 21.23% | 3115 23.02% | 2532 18.06% | 2145 15.06% | 1864 41.59% | 1317 39.82% | 942 -20.22% | 1180 14.28% |
| Profit (INR Cr) | 1600 -12.3% | 1824 -38.4% | 2960 49.2% | 1984 44.2% | 1377 1.8% | 1353 54.2% | 877 -17.3% | 1060 -5.8% | 1126 32.2% | 852 10.1% | 773 28.5% | 602 12.9% | 533 24.2% | 429 26.1% | 340 -18.3% | 417 - |
| Assets (INR Cr) | 13611 6.3% | 12802 8.9% | 11759 26.1% | 9325 26.5% | 7369 4.2% | 7076 17.9% | 6003 11.0% | 5408 24.4% | 4347 23.2% | 3529 18.2% | 2985 17.7% | 2536 15.5% | 2195 19.8% | 1833 18.2% | 1551 19.8% | 1294 - |
| Net Worth (INR Cr) | 13571 6.3% | 12767 8.9% | 11728 26.2% | 9295 27.2% | 7310 5.1% | 6957 17.4% | 5925 10.6% | 5357 24.8% | 4293 22.8% | 3495 18.0% | 2963 18.5% | 2501 17.3% | 2132 18.6% | 1797 18.4% | 1518 22.3% | 1241 44.1% |
| Employee Cost (INR Cr) | 1094 12.2% | 975 3.1% | 946 14.6% | 826 33.0% | 621 14.5% | 542 18.9% | 456 -8.8% | 500 38.4% | 361 24.4% | 290 24.9% | 232 17.6% | 198 31.1% | 151 28.7% | 117 64.2% | 71 13.6% | 63 - |
| Interest Cost (INR Cr) | 4 | 2 | 2 | 2 | 7 | 5 | 2 | 3 | 5 | 3 | 3 | 3 | 5 | 2 | 3 | 7 |
| Cash & Bank Balance (INR Cr) | 3980 | 4214 | 2819 | 2156 | 123 | 115 | 112 | 79 | 73 | 65 | 41 | 41 | 31 | 18 | 16 | 15 |
| Total Debt (INR Cr) | 3 | 4 | 4 | 5 | 39 | 106 | 63 | 36 | 42 | 27 | 18 | 33 | 55 | 23 | 33 | 53 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 19.3% | 22.6% | 30.9% | 27.9% | 24.2% | 25.0% | 21.9% | 25.4% | 29.3% | 25.1% | 28.4% | 26.3% | 27.6% | 32.5% | 31.8% | 31.5% |
| Profit As % Of Assets | 11.8% | 14.3% | 25.2% | 21.3% | 18.7% | 19.1% | 14.6% | 19.6% | 25.9% | 24.1% | 25.9% | 23.7% | 24.3% | 23.4% | 22.0% | 32.2% |
| Profit As % Of Networth | 11.8% | 14.3% | 25.2% | 21.4% | 18.8% | 19.4% | 14.8% | 19.8% | 26.2% | 24.4% | 26.1% | 24.1% | 25.0% | 23.9% | 22.4% | 33.6% |
| Interest Cost to EBITDA % | 0.2% | 0.1% | 0.1% | 0.1% | 0.4% | 0.3% | 0.2% | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% | 0.7% | 0.5% | 0.7% | 1.5% |
| Debt to Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 | 0.02 | 0.04 |
| RONW | 12.2% | 14.9% | 28.2% | 23.9% | 19.3% | 21.0% | 15.6% | 22.0% | 28.9% | 26.4% | 28.3% | 26.0% | 27.1% | 25.9% | 24.7% | 39.6% |
| ROCE | 16.4% | 19.3% | 35.0% | 32.0% | 25.3% | 28.4% | 21.6% | 28.7% | 35.5% | 33.0% | 36.0% | 33.1% | 34.0% | 28.1% | 27.3% | 40.6% |